Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Cangzhou, China Clinical Trials

A listing of Cangzhou, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

Remote Ischemic Conditioning for Avoiding Recurrence of Symptomatic Intracranial Atherosclerotic Stenosis (sICAS)

In this study, Patients in the RLIC group will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate) (200mmHg) once daily for 12 months; patients in the sham RLIC group will be treated with the Renqiao Remote Ischemic Conditioning Device (Doctormate) (60mmHg) once daily for 12 months. In the study, ...

Phase N/A

0.0 miles

Learn More »

BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study

This study is a prospective, multicentred randomized controlled trial, planning to enroll 430 subjects and randomize 1:1 to study group and control group. All subjects will accepte clinical evaluation at 1 month, 6 month, 9 month and 1, 2, 3, 4, 5 year post procedure. All subjects will accepte angiographic ...

Phase N/A

0.0 miles

Learn More »

Mobile Lung Nodule Observatory for Worldwide Evidenced-based Research

Lung nodules can manifest as single or multiple independent lung consolidation shadow in form of quasi-circular. These lung nodules are surrounded by normal lung tissues, and will not cause pulmonary atelectasis. In some early standards, all the quasi-circular shadows within 6cm found in lung are categorized as lung nodules. However, ...

Phase N/A

0.0 miles

Learn More »

Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)

Since strategies were applied in intensive care medicine, including low tidal volume ventilation, fluid resuscitation, use of antibiotics, restrictive transfusion strategy and bundle of ventilator therapy, the incidence of Acute Respiratory Distress Syndrome (ARDS) has been decreased recent years. However, the mortality of severe ARDS is still higher to 45%. ...

Phase N/A

0.0 miles

Learn More »